Does MTRR rs1801394 AG reduce methionine synthase support and homocysteine clearance resilience?

The MTRR rs1801394 polymorphism alters a critical enzyme in the one-carbon metabolism pathway, directly affecting how the body processes and clears homocysteine.

Molecular mechanisms

• Enzymatic Reactivation: The MTRR rs1801394 (A66G, I22M) variant is located near the enzyme’s FMN-binding domain. This structural alteration decreases MTRR's binding affinity for methionine synthase (MTR), impairing its ability to regenerate oxidized cobalamin into its active methylcobalamin form.
• Intermediate Kinetics: While wild-type (AA) individuals exhibit normal MTR reactivation and homozygotes (GG) experience a substantial ~4-fold reduction in activity, heterozygous (AG) individuals exhibit intermediate reactivation kinetics and moderately reduced MTRR activity.

Homocysteine clearance and B12 status

• Impaired Remethylation: Because MTR drives the conversion of homocysteine to methionine, a reduction in MTRR-mediated cofactor recycling compromises the resilience of the overall remethylation pathway under metabolic stress.
• Intracellular Disconnect: This clearance vulnerability persists even in the presence of adequate serum vitamin B12 levels. Normal circulating B12 concentrations do not guarantee efficient intracellular utilization or activation, meaning a functional, localized cobalamin recycling deficit remains in AG heterozygotes. This vulnerability is especially pronounced during nutrient fluctuations or in combination with other variants like MTHFR C677T.

Bottom line

• Bottom line: The heterozygous MTRR rs1801394 AG genotype moderately reduces cobalamin recycling efficiency and MTR reactivation kinetics. This compromises the resilience of homocysteine clearance under metabolic stress, a functional deficit that persists despite adequate circulating serum vitamin B12 levels.